Login
Home / VS : NASDAQ
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Versus Systems Inc.

$1.1 -$0.15 (-12.00%)
NASDAQ · 15 Sep 2026 16:08 UTC
Previous Close
$1.03
Day Range
$1.06$1.21
Year Range
$0.75$2.47
Market Cap
5.39M
AVG Volume
37.48K
Trailing/Forward PE
-2.3/-
PEG ratio
0.17
Dividend Yield
-
Next Earnings Date
2026-11-17
Primary Exchange
NASDAQUS
Revenue (USD)
0500K1M1.5M2M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Net Income (USD)
-2M-1M01M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Operating Income (USD)
-2M-1M01M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EBITDA (USD)
-2M-1M01M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash Flows (USD)
-2M-1M01M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
EPS (USD)
-0.6-0.4-0.2-00.224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Expenses (USD)
-500K0500K1M1.5M2MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Cash & Debt (USD)
02M4M6MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Debt ratios
00.511.524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Margins
-50%0%50%100%23 Q323 Q424 Q124 Q224 Q325 Q125 Q225 Q426 Q126 Q2
Return on Capital
-75%-50%-25%0%25%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Shares Outstanding
02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Book Value Per Share (USD)
00.511.5224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Total Assets (USD)
02M4M6M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
Employee Count
051015202022202320242025
Free Cash Flow Yield
-150%-100%-50%0%med -36%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Sales
050100150med 4.47Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Book
02468med 2.73Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Versus Systems Inc.
VS
Stockpicker

Video analysis: VS

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: VS

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

businesswire.com · 23 Jun 2026

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.